secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001087294-26-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M
--------------------------------------------------------------------------------

- Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.
- Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.
- Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.
- Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.
- Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/0001087294-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/cpix-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer